Skip to content

SORRENTO THERAPEUTICS, INC.: 10-Q filed 2012-11-08

What SORRENTO THERAPEUTICS, INC. reported in its quarterly report filed 2012-11-08 (fiscal Q3 2012): 28 published measures, 85 facts as tagged in accession 0001193125-12-458730.

This filing

Form
10-Q (quarterly report)
Filed
2012-11-08
Fiscal period
fiscal Q3 2012
Accession
0001193125-12-458730 on SEC EDGAR

Values are as tagged in this filing. A later filing can restate them; a measure with a published history links to it, and the history shows the latest-filed value per period. All SORRENTO THERAPEUTICS, INC. filings.

Reported measures

Total assets

Resources recognized on the balance sheet. Book assets are not the market value of the business.

PeriodValueUnitDays
At 2012-09-307,891,563USD
At 2011-12-314,568,828USD

Stockholders equity

The reported residual interest after liabilities. It is an accounting amount, not market capitalization.

PeriodValueUnitDays
At 2012-09-307,347,319USD
At 2011-12-314,209,489USD

Cash and cash equivalents

Cash and qualifying short-term liquid investments under the filer’s accounting policy. Restricted cash and longer-term investments may be reported separately.

PeriodValueUnitDays
At 2012-09-306,445,441USD
At 2011-12-313,466,549USD
At 2011-09-302,270,416USD
At 2010-12-315,277,578USD

Net income or loss

Reported profit or loss for the period. Check the filing for attribution, exceptional items and discontinued operations before comparing companies.

PeriodValueUnitDays
2012-07-01 to 2012-09-30-1,241,229USD92
2012-01-01 to 2012-09-30-3,090,473USD274
2006-01-25 to 2012-09-30-9,195,464USD2441
2011-06-30 to 2011-09-30-702,288USD93
2011-01-01 to 2011-09-30-2,474,368USD273

Operating cash flow

Cash generated or used by operating activities. Working-capital timing can make this differ substantially from reported income.

PeriodValueUnitDays
2012-01-01 to 2012-09-30-2,468,243USD274
2006-01-25 to 2012-09-30-7,463,267USD2441
2011-01-01 to 2011-09-30-2,204,385USD273

Capital expenditure payments

Cash payments to acquire property, plant and equipment. This taxonomy concept does not capture every form of investment or acquisition.

PeriodValueUnitDays
2012-01-01 to 2012-09-30491,096USD274
2006-01-25 to 2012-09-301,664,928USD2441
2011-01-01 to 2011-09-30810,609USD273

Revenue

Revenue under this specific accounting concept. A missing value is not zero; filers can use other revenue concepts.

PeriodValueUnitDays
2012-07-01 to 2012-09-30134,506USD92
2012-01-01 to 2012-09-30461,790USD274
2006-01-25 to 2012-09-301,673,542USD2441
2011-06-30 to 2011-09-3091,756USD93
2011-01-01 to 2011-09-30401,277USD273

Financing cash flow

Net cash from financing activities, including borrowing, repayments and transactions with owners. A positive amount does not establish operating profitability.

PeriodValueUnitDays
2012-01-01 to 2012-09-305,938,231USD274
2006-01-25 to 2012-09-3015,468,776USD2441
2011-01-01 to 2011-09-307,832USD273

Investing cash flow

Net cash from investing activities, including asset purchases, disposals and investment transactions. This differs from capital expenditure payments alone.

PeriodValueUnitDays
2012-01-01 to 2012-09-30-491,096USD274
2006-01-25 to 2012-09-30-1,560,068USD2441
2011-01-01 to 2011-09-30-810,609USD273

Retained earnings or deficit

Accumulated undistributed earnings or deficit at the reporting date. This balance is not cash available for distribution.

PeriodValueUnitDays
At 2012-09-309,195,464USD

Net property, plant and equipment

Carrying amount of property, plant and equipment after accumulated depreciation, depletion and amortization. It is not replacement cost or market value.

PeriodValueUnitDays
At 2012-09-301,270,503USD
At 2011-12-31988,445USD

Share-based compensation expense

Reported noncash expense for share-based payment arrangements. Noncash treatment does not mean the awards have no economic cost to shareholders.

PeriodValueUnitDays
2012-01-01 to 2012-09-30290,072USD274
2006-01-25 to 2012-09-30893,584USD2441
2011-01-01 to 2011-09-30221,323USD273

Operating income or loss

Operating revenue less operating expenses for the reporting period. It excludes items outside the reported operating result and is not free cash flow.

PeriodValueUnitDays
2012-07-01 to 2012-09-30-1,243,347USD92
2012-01-01 to 2012-09-30-3,095,819USD274
2006-01-25 to 2012-09-30-9,222,404USD2441
2011-06-30 to 2011-09-30-703,666USD93
2011-01-01 to 2011-09-30-2,479,122USD273

Current assets

Assets classified as current under the normal operating cycle or one-year boundary. Not all current assets can be converted immediately into cash.

PeriodValueUnitDays
At 2012-09-306,598,333USD
At 2011-12-313,557,656USD

Current liabilities

Obligations classified as current under the operating-cycle or one-year boundary. The balance includes more than short-term borrowing.

PeriodValueUnitDays
At 2012-09-30544,244USD
At 2011-12-31359,339USD

Current accounts payable

Current amounts owed to suppliers for goods and services received. This is one component of current liabilities, not all accrued obligations.

PeriodValueUnitDays
At 2012-09-30394,528USD
At 2011-12-31224,742USD

Operating expenses

Recurring operating costs under this accounting concept, generally excluding production costs included in cost of sales. Check filing presentation before combining expense subtotals.

PeriodValueUnitDays
2012-07-01 to 2012-09-301,377,853USD92
2012-01-01 to 2012-09-303,557,609USD274
2006-01-25 to 2012-09-3010,895,946USD2441
2011-06-30 to 2011-09-30795,422USD93
2011-01-01 to 2011-09-302,880,399USD273

Research and development expense

Research and development costs recognized as expense. Capitalization policies and acquired projects can make this differ from total cash invested in development.

PeriodValueUnitDays
2012-07-01 to 2012-09-30950,823USD92
2012-01-01 to 2012-09-302,667,347USD274
2006-01-25 to 2012-09-307,040,269USD2441
2011-06-30 to 2011-09-30636,453USD93
2011-01-01 to 2011-09-301,861,398USD273

Common shares outstanding

Common shares outstanding at the reporting date. This point-in-time count differs from the weighted-average shares used for earnings per share and can exclude other share classes.

PeriodValueUnitDays
At 2012-09-30299,877,135shares
At 2011-12-31262,347,135shares
At 2009-09-1711,073,946shares

Additional paid-in capital

Capital contributed above par value under this concept. It records historical contributions, not the current value of the equity or cash on hand.

PeriodValueUnitDays
At 2012-09-3016,512,795USD
At 2011-12-3110,288,245USD

Other noncurrent assets

Noncurrent assets the filer does not present separately. The composition differs by filer and is described only in the filing.

PeriodValueUnitDays
At 2012-09-3022,727USD
At 2011-12-3122,727USD

Accrued current liabilities

Current obligations accrued for goods and services received but not yet invoiced or paid. This is one component of current liabilities, not all short-term obligations.

PeriodValueUnitDays
At 2012-09-3061,872USD
At 2011-12-3146,087USD

Prepaid expenses and other current assets

Prepayments and other current assets grouped under this concept. The balance is not cash and its composition differs by filer.

PeriodValueUnitDays
At 2012-09-3066,816USD
At 2011-12-3129,869USD

General and administrative expense

General and administrative costs reported under this concept, separate from selling expense. Filers group overhead differently, so compare presentation before comparing companies.

PeriodValueUnitDays
2012-07-01 to 2012-09-30427,030USD92
2012-01-01 to 2012-09-30890,262USD274
2006-01-25 to 2012-09-303,855,677USD2441
2011-06-30 to 2011-09-30158,969USD93
2011-01-01 to 2011-09-301,019,001USD273

Depreciation, depletion and amortization

Combined depreciation, depletion and amortization for the period. A noncash allocation of asset cost, not a measure of maintenance spending.

PeriodValueUnitDays
2012-01-01 to 2012-09-30209,038USD274
2006-01-25 to 2012-09-30394,425USD2441
2011-01-01 to 2011-09-30104,022USD273

Income taxes paid, net

Cash income taxes paid net of refunds during the period. It differs from income tax expense and can reflect prior years and estimated payments.

PeriodValueUnitDays
2012-01-01 to 2012-09-30800USD274
2006-01-25 to 2012-09-304,800USD2441
2011-01-01 to 2011-09-30800USD273

Proceeds from issuing common stock

Cash received from issuing common stock during the period. It is gross of costs only where the filer reports it so, and it does not include noncash issuances.

PeriodValueUnitDays
2012-01-01 to 2012-09-305,934,031USD274
2006-01-25 to 2012-09-3015,451,451USD2441
2011-01-01 to 2011-09-30-43USD273

Change in accounts payable

The cash flow adjustment for the change in payables during the period. A positive value under this concept means payables grew and added to operating cash flow.

PeriodValueUnitDays
2012-01-01 to 2012-09-30169,786USD274
2006-01-25 to 2012-09-30369,904USD2441
2011-01-01 to 2011-09-30-70,349USD273

Inspect the source

Entity
SORRENTO THERAPEUTICS, INC. / CIK 0000850261
Captured
SEC response SHA-256
52c2f17674a4b77d02e740899926ba7e57965bff74d27d5e57742ede3dd5745d

Current SEC company facts · Download the original response snapshot (gzip) · Download the selected JSON

Every published concept a filing tagged, with the periods it covered, as reported in that filing at capture time. Forms 10-K, 10-K/A, 10-Q, 10-Q/A, 20-F, 20-F/A, 40-F, 40-F/A. A filing page needs at least 8 published concepts. Later filings can restate these values; the company history pages show the latest-filed value per period.

Public company accounting reference, not market prices, returns, an investment recommendation, or ALPHAC performance. Validate a separately constructed return series with the validation API; accounting values are not returns.

Use this in research

A financial period ends before its results become public. Use the filing date as a minimum availability boundary, inspect amendments, and retain the original filing vintage when testing historical signals. This latest-filed selection can contain information unavailable at the time.

These pages do not supply prices, total-return histories, corporate-action adjustments or a tradable universe. Build those inputs separately before evaluating a strategy. A profitable backtest can still reflect selection bias or costs that were left out.

Research methodology · Execution and cost assumptions · Check backtest overfitting

Build with the open-source tools

Use these accounting records as inspectable inputs. When you have constructed a return series, the validation tools can help test its statistical evidence and preserve the result with its limitations.

Read the published dataset with Python
import json
from urllib.request import urlopen

with urlopen("https://canlicapital.com/company-data/0000850261.json") as response:
    record = json.load(response)
print(record["fetched_at"])
print(record["policy"])
for concept in record["concepts"]:
    print(concept["tag"], next(iter(concept["observations"])))